Serum Gamma-Glutamyl Transferase as a Biomarker for Insulin Resistance and Metabolic Syndrome in Dhaka, Bangladesh: A Cross-Sectional Study
Abdinasir AliMohamud
Abdinasir Ali Mohamud, Department of Internal Medicine, University of Somalia, abdinasirali01@gmail.com
Mohamed NurMohamed
Mohamed Nur Mohamed, Department of Public Health, World University of Bangladesh (WUB), mohamednuur9920@gmail.com
Md. AshiqurRahman
Md. Ashiqur Rahman, Department of Laboratory Medicine, Novus Clinical Research Services Limited (NCRSL), Bangladesh, ararashiqur@gmail.com
Sadia Islam
Sadia Islam, Department of Laboratory Medicine, Bangladesh Specialized Hospital, Bangladesh, sadia.buhs.6700@gmail.com
DOI: https://doi.org/mmr.v2i1.7097
Keywords: Gamma-glutamyl transferase; HOMA-IR; Metabolic syndrome; Biomarker; Lipid Profile
Abstract
Background: Gamma-glutamyl transferase is an enzyme found in various tissues, including the liver, kidney, pancreas, and intestine. Elevated serum GGT levels are linked to oxidative stress and cardiovascular risk factors. GGT plays a role in glutathione catabolism, potentially leading to metabolic disturbances like insulin resistance and metabolic syndrome. Objective: The study explores the link between serum GGT levels and insulin resistance in Dhaka, Bangladesh, aiming to assess serum GGT's potential as a biomarker for insulin resistance and metabolic syndrome. Methods: The study was conducted at a hospital in Dhaka, Bangladesh, involving 330 participants aged 20 to 60, with 147 diagnosed with metabolic syndrome (MetS) and 183 without. Anthropometric data were collected, and fasting blood samples were analyzed. Statistical analysis was performed using SPSS software, with results compared using unpaired Student’s t-test and ANOVA, considering a p-value
References
1.Scott, R., Donoghoe, M., Watts, G.F., O'Brien, R., Pardy, C., Taskinen, M.R., Davis, T.M., Colman, P.G., Manning, P., Fulcher, G. and Keech, A.C., 2011. Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovascular Diabetology, 10(1), p.102.
2.International Diabetes Federation, 2006. The IDF consensus worldwide definition of the metabolic syndrome. IDF Communications, pp.1-23.
3.Singh, B. and Saxena, A., 2010. Surrogate markers of insulin resistance: A review. World Journal of Diabetes, 1(2), p.36.
4.Burtis, C.A. and Bruns, D.E., 2014. Tietz fundamentals of Clinical Chemistry and Molecular Diagnostics, 7th edn, Elsevier, St. Louis, Missouri, USA.
5.Meisinger, C., Döring, A., Schneider, A. and Löwel, H., 2006. Serum γ-glutamyltransferase is a predictor of incident coronary events apparently healthy men from the general population. Atherosclerosis, 189(2), pp.297-302.
6.Mason, J.E., Starke, R.D. and Van Kirk, J.E., 2010. Gamma‐Glutamyl transferase: a novel cardiovascular risk BioMarker. Preventive Cardiology, 13(1), pp.36-41.
7.Hotamisligil, G.S., 2003. Inflammatory pathways and insulin action. International Journal of Obesity, 27(S3), p.S53.
8.Park, Y.W., Zhu, S., Palaniappan, L., Heshka, S., Carnethon, M.R. and Heymsfield, S.B., 2003. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Archives of Internal Medicine, 163(4), pp.427-436.
9.Kavsak, P., 2017. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, edited by Nader Rifai, Andrea Rita Horvath and Carl T. Wittwer,6th edn, Elsevier, St. Louis, Missouri, USA.
10.Nestel, P., Lyu, R., Low, L.P., Sheu, W.H.H., Nitiyanant, W., Saito, I. and Tan, C.E., 2007. Metabolic syndrome: recent prevalence in East and Southeast Asian populations. Asia Pacific Journal of Clinical Nutrition, 16(2), pp.362-367.
11.Mainuddin, A.K.M., Choudhury, K.N., Ahmed, K.R., Akter, S., Islam, N. and Masud, J.H.B., 2013. The metabolic syndrome: comparison of newly proposed IDF, modified ATP III and WHO criteria and their agreements. Cardiovascular Journal, 6(1), pp. 17-22.
12.Chowdhury, M.Z.I., Anik, A.M., Farhana, Z., Bristi, P.D., Al Mamun, B.A., Uddin, M.J., Fatema, J., Akter, T., Tani, T.A., Rahman, M. and Turin, T.C., 2018. Prevalence of metabolic syndrome in Bangladesh: a systematic review and meta-analysis of the studies. BMC Public Health, 18(1), p.308.
13.Borai, A., Livingstone, C. and Ferns, G.A., 2007. The biochemical assessment of insulin resistance. Annals of Clinical Biochemistry, 44(4), pp.324-342.
14.Lee, D.H., Blomhoff, R. and Jacobs, D.R., 2004. Review is serum gamma glutamyltransferase a marker of oxidative stress. Free Radical Research, 38(6), pp.535-539.
15.Nakanishi, N., Suzuki, K. and Tatara, K., 2004. Serum γ-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care, 27(6), pp.1427-1432.
16.Inoue, K., Hirohara, J., Nakano, T., Seki, T., Sasaki, H., Higuchi, K., Ohta, Y., Onji, M., Muto, Y. and Moriwaki, H., 1995. Prediction of prognosis of primary biliary cirrhosis in Japan. Liver, 15(2), pp.70-77.
17.Whitfield, J.B., 2001. Gamma glutamyl transferase. Critical Reviews in Clinical Laboratory Sciences, 38(4), pp.263-355.
18.Lee, D.H., Ha, M.H., Kim, J.H., Christiani, D.C., Gross, M.D., Steffes, M., Blomhoff, R. and Jacobs, D.R., 2003. Gamma-glutamyltransferase and diabetes—a 4 year follow-up study. Diabetologia, 46(3), pp.359-364.
19.Chanda M, Biswas T, Roy MN, Sampa SR, Saha P, Sharna RJ, Islam S, Mahbub A, Rahman MA. Association of Liver Enzymes and Lipid Profile in Adults at Tertiary Level Hospitalin Bangladesh. J Natl Inst Lab Med Ref Bangladesh. 2021;1(1):17-24.
20.Kim, J.Y., Dhananjay, D., Ahn, S.V., Koh, S.B., Son, J.W., Lee, J.W., Youn, Y.J., Ahn, M.S., Ahn, S.G., Yoo, B.S. and Lee, S.H., 2016. Ps 11-70 A Prospective study Of serum γ-glutamyltransferase levels and incident of Metabolic Syndrome: The Arirang Study. Journal of Hypertension, 34, p.352.
21.Marchesini, G., Avagnina, S., Barantani, E.G., Ciccarone, A.M., Corica, F., Dall’Aglio, E., Dalle Grave, R., Morpurgo, P.S., Tomasi, F. and Vitacolonna, E., 2005. Aminotransferase and gamma-glutamyl transpeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. Journal of Endocrinological Investigation, 28(6), pp.333-339.
22.Kawamoto, R., Kohara, K., Tabara, Y., Miki, T. and Otsuka, N., 2009. Serum gamma-glutamyltransferase levels are associated with metabolic syndrome in community-dwelling individuals. Journal of Atherosclerosis and Thrombosis, 16(4), pp.355-362.
23.Xie, J., Zhang, S., Yu, X., Yang, Y., Liu, Z., Yuan, G. and Hu, S., 2018. Association between liver Enzymes with metabolically unhealthy obese phenotype. Lipids in Health and Disease, 17(1), p.198.
24.Lawlor, D.A., Sattar, N., Smith, G.D. and Ebrahim, S., 2005. The associations of physical activity and adiposity with alanine aminotransferase and gamma-glutamyltransferase. American Journal of Epidemiology, 161(11), pp.1081-1088.
25.Masilamani, V., Gopinath, P., Kandasamy, S. and Kumar, A., 2016. Association of Gamma-glutamyl transferase with Metabolic syndrome. Medicine and Healthcare, 3(100), pp.5498-5502
26.Sakugawa, H., Nakayoshi, T., Kobashigawa, K., Nakasone, H., Kawakami, Y., Yamashiro, T., Maeshiro, T., Tomimori, K., Miyagi, S., Kinjo, F. and Saito, A., 2004. Metabolic syndrome is directly associated with gamma glutamyl transpeptidase elevation in Japanese women. World Journal of Gastroenterology, 10(7), p.1052.
27.Gorter, P.M., Olijhoek, J.K., van der Graaf, Y., Algra, A., Rabelink, T.J., Visseren, F.L. and SMART Study Group, 2004. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis, 173(2), pp.361-367.
28.Kolovou, G.D., Anagnostopoulou, K.K. and Cokkinos, D.V., 2005. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgraduate Medical Journal, 81(956), pp.358-366.
29.Kang, Y.H., Min, H.K., Son, S.M., Kim, I.J. and Kim, Y.K., 2007. The association of serum gamma glutamyltransferase with components of the metabolic syndrome in the Korean adults. Diabetes Research and Clinical Practice, 77(2), pp.306-313.
30.Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A.J., Natale, S., Forlani, G. and Melchionda, N., 2001. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes, 50(8), pp.1844-1850.
31.Kerner, A., Avizohar, O., Sella, R., Bartha, P., Zinder, O., Markiewicz, W., Levy, Y., Brook, G.J. and Aronson, D., 2005. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular biology, 25(1), pp.193-197.
32.Lindsay, R.S., Funahashi, T., Hanson, R.L., Matsuzawa, Y., Tanaka, S., Tataranni, P.A., Knowler, W.C. and Krakoff, J., 2002. Adiponectin and development of type 2 diabetes in the Pima Indian population. The Lancet, 360(9326), pp.57-58.
33.Lomonaco, R., Ortiz‐Lopez, C., Orsak, B., Webb, A., Hardies, J., Darland, C., Finch, J., Gastaldelli, A., Harrison, S., Tio, F. and Cusi, K., 2012. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology, 55(5), pp.1389-1397.
34.Abdiaziz AA, Hossain MB, Mahbub A, Islam S, Rahaman S, Rahman MA. Prevalence of Abnormal Lipid Profile Among Obese People in Mogadisho, Somalia. Asian Journal of Medicine and Health. 2024 Jun 26;22(7):194-203.